Important Safety Information for Microdose GLP-1/GIP

What is Microdose GLP-1/GIP?

Microdose GLP-1/GIP is a low-dose compounded tirzepatide formulation designed for metabolic optimization and longevity support rather than aggressive weight loss. Tirzepatide is a dual-action medication that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, supporting insulin sensitivity, metabolic balance, and inflammatory reduction at lower doses than those used for weight management.

Important Warning: Thyroid Tumor Risk

Tirzepatide has been associated with thyroid C-cell tumors in animal studies. The relevance to humans is currently unknown. Do not use this medication if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Notify your healthcare provider immediately if you experience:

• A lump or mass in your neck
• Persistent hoarseness or voice changes
• Difficulty swallowing
• Shortness of breath that doesn't resolve

Who Should Not Use Microdose GLP-1/GIP?

This medication is not appropriate for individuals who:

• Have a personal or family history of medullary thyroid carcinoma
• Have been diagnosed with Multiple Endocrine Neoplasia syndrome type 2
• Have experienced a serious allergic reaction to tirzepatide or any component of this medication
• Have severe gastrointestinal disorders including gastroparesis
• Are pregnant, planning to become pregnant, or breastfeeding
• Have a history of pancreatitis

Warnings and Precautions

1. Pancreatitis RiskEven at low doses, tirzepatide may cause inflammation of the pancreas. Discontinue use immediately if you develop severe, persistent abdominal pain that may radiate to your back, with or without vomiting. Do not resume therapy if pancreatitis is confirmed by your healthcare provider.

2. Blood Sugar EffectsAlthough microdosing is intended for metabolic support rather than diabetes treatment, tirzepatide can affect blood sugar levels. If you take insulin or other diabetes medications, discuss potential interactions with your provider. Monitor for signs of low blood sugar including shakiness, sweating, confusion, and rapid heartbeat.

3. Kidney ConsiderationsDehydration from gastrointestinal side effects may affect kidney function. Maintain adequate hydration, especially if you experience nausea, vomiting, or diarrhea. Patients with existing kidney conditions should be monitored more closely.

4. Gallbladder IssuesGLP-1/GIP medications may increase the risk of gallstones and gallbladder inflammation. Contact your provider if you experience sudden upper abdominal pain, particularly on the right side, with or without fever or nausea.

5. Allergic ReactionsSerious hypersensitivity reactions including anaphylaxis and angioedema have been reported with tirzepatide. Seek emergency medical care immediately if you experience facial swelling, throat tightness, difficulty breathing, severe rash, or rapid heartbeat.

6. Gastrointestinal EffectsNausea, constipation, diarrhea, and stomach discomfort may occur, though these effects are typically milder at microdose levels. Report persistent or severe GI symptoms to your provider.

Common Side Effects

At microdose levels, side effects are generally milder than with standard dosing. You may experience:

• Mild nausea
• Decreased appetite
• Constipation or diarrhea
• Fatigue
• Injection site reactions (redness, mild swelling, or tenderness)
• Headache

Most side effects diminish as your body adjusts to the medication.

Pregnancy and Breastfeeding

Pregnancy: Do not use microdose tirzepatide during pregnancy. Based on animal studies, this medication may cause harm to a developing fetus. Discontinue use at least 4 weeks before attempting pregnancy.

Breastfeeding: It is unknown whether tirzepatide passes into breast milk. Due to potential risks to nursing infants, discuss with your healthcare provider whether to discontinue breastfeeding or the medication.

Drug Interactions

Inform your provider about all medications you take, including:

• Insulin and oral diabetes medications
• Blood thinners
• Oral contraceptives (absorption may be affected)
• Other GLP-1 or GIP-based medications (do not combine)
• Medications requiring specific timing for absorption

Storage and Administration

• Store in refrigerator before first use; may be kept at room temperature after opening
• Administer subcutaneously (under the skin) as directed by your provider
• Rotate injection sites with each dose
• Follow your prescribed dosing schedule carefully
• Do not share injection supplies with others

When to Seek Medical Attention

Contact your healthcare provider or seek emergency care if you experience:

• Severe or persistent abdominal pain
• Signs of allergic reaction (swelling, rash, difficulty breathing)
• Symptoms of severe dehydration
• A lump in your neck or persistent hoarseness
• Any concerning symptoms that do not resolve

Reporting Side Effects

Report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

This information is not comprehensive. Consult your healthcare provider for complete safety information about microdose tirzepatide.